The American Cancer Society and St. Baldrick’s Foundation recently awarded $1.2 million in a second round of Pilot Accelerator grants requiring researchers to use clinical trials to accelerate treatment options for childhood cancer.
New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
